conferenceseries.com

EBC 2017

4TH EUROPEAN BIOPHARMA CONGRESS

November 09-11, 2017 // Vienna, Austria

4th European Biopharma Congress



Vienna, Austria

November 09-11, 2017

eurobiopharma@pharmaceuticalconferences.org

Euro Biopharma 2017

Invitation

Dear Attendees,

We are glad to announce the **4th European Biopharma Congress** to be held in **Vienna, Austria** from **November 09-11, 2017** organized by **Conference Series** in collaboration with generous support and cooperation from enthusiastic academicians and editorial Board Members.

This conference is a unique international platform that's a confluence of all stake holders of the ecosystem – Industry, Academia, Researchers, Innovators, Regulators – coming together to present and discuss current topics in Cell Therapy, Biopharmaceutics, Drug delivery, Biotechnology, Gene Therapy, Therapeutic Biological Products, BABE, Biosimilars, Clinical Trails, Drug Discovery, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, new scientific approaches to international regulatory standards. Biopharmaceutical Companies & Pharma market Analysis, and will be available to discuss with you the latest issues and trends in ***Market Scopes & R&D challenges of Biopharmaceuticals- Cost, Complexity & Regulatory Scrutiny***

As the premier event, we have developed a program with your interests in mind. We have not only increased the number of opportunities for you to network with colleagues from across the world but also introduced more focused sessions that will feature cutting edge presentations, special panel discussions, and livelier interaction with industry leaders and experts.

Life is full of give and take. Make it count in your professional life. Attend the Biopharmaceutical Conference to network with your peers, exchange expertise and experiences, and arm yourself with the latest information to take your department to the next level.

We look forward to personally welcoming you to **Vienna** this November.

Sincerely,
Euro Biopharma 2017
Organizing Committee

Market Analysis of Biopharma

The opportunity in biopharmaceuticals is big and growing too rapidly to ignore. Today, biopharmaceuticals generate global revenues of $163 billion, making up about 20%of the pharma market. It's by far the fastest-growing part of the industry: biopharma's current annual growth rate of more than 8% is double that of conventional pharma, and growth is expected to continue at that rate for the foreseeable future.

The world of Big Pharma is not only growing, it's standing on its head. Worldwide spending for prescription branded drugs and generic medicines will jump 30% from 2013-2018 at compound annual growth rate of over 5% leading to a jaw-dropping $1.3 trillion in annual global drug sales. The Pharma market is also radically shifting position, with traditional strongholds, such as Japan and Europe, flipping over, and The viability and wellbeing of biopharmaceutical items, joined with their capacity to address already untreatable conditions, permits pharma organizations to charge high costs for imaginative medications. Solid request has driven critical benefits, in spite of the high cost of products sold.

Biopharmaceuticals have set new gauges for blockbuster tranquilizes also. Blockbusters are customarily characterized as medications that have $1 at least billion in yearly deals; the main 15 biopharma items each appreciate yearly income of more than $2 billion, with a few, for example, the calming drug Humira, creating offers of more than $10 billion a year. For some players, the greatest test has been basically making enough item The achievement of the clinical pipeline will prompt to an uncommon number of new atom dispatches, ascending from a modest bunch a couple of years back to 10 to 15 every year, as biopharma items make up an expanding offer of new endorsements from the US Food and Drug Administration later on. A further soak increment is not out of the ordinary as different players get endorsement for the generation of biosimilars after 2015.

On the off chance that anything, the rising long haul picture is significantly all the more energizing, with problematic advancements, for example, immunotherapies, neutralizer tranquilize conjugates, and quality and cell treatments all gaining ground toward business dispatch in the following couple of years. Biopharma looks ready to change the business again, as expanding comprehension of the cooperation amongst medications and the hereditary cosmetics of patients enhances the focusing of treatments. Joined with hearty, minimal effort hereditary profiling, this learning will enhance treatment results and serve to quicken and enhance the results of clinical trials, diminishing the cost of medication advancement.

Market Analysis of Biopharma

Worldwide trend-setters should drive item development with a specific end goal to keep on commanding premium costs, moving the outskirts of innovation and investigating new operational setups, (for example, the outline and sending of their future system). Biosimilars players should concentrate on cost, quality, and scale. For them, speed, prepare development, and operational brilliance are must-win fights. Players situated in developing business sector countries should locate their own particular specialties with the privilege operational and quality execution to make the best utilization of favored access to, and information of, their neighborhood pharma markets. Contract-producing associations should be at the main edge of process development and operational productivity while holding or building a spotless notoriety for administration and execution. Past these non specific player models, every organization will require a point by point perspective of its own vital position, approaching itself what it remains for in the Pharma market and what it needs to do keeping in mind the end goal to win.

We trust that the biopharmaceutical organizations best situated to prevail in tomorrow's Pharma market will be those that ace an expansive arrangement of specialized and operational abilities. Choices that organizations are making today will impact that accomplishment for two critical reasons. To start with, operational fabulousness is a hard-won ability. Abilities, for example, incline, light-footed, and effective assembling require managed exertion and responsibility to form and hardwire into the association. Second, choices made today will influence organizations' focused positions years or even decades into what's to come. This is especially valid in zones, for example, impression outline and the decision of center assembling innovations.

A full dialog of all the specialized and operational choices confronting biopharma organizations today and in the coming years, however probably the most critical contemplations incorporate the accompanying


The prize for associations that ace these operational difficulties is much more critical than simply here and now upper hand. A number of the following real open doors for biotech will oblige organizations to grow new and diverse innovations and working models. Today's activities will shape organizations' preparation to get a handle on these open astonishingly to fulfillment.

Toward one side of the scale, for instance, the industry must build up the abilities to rapidly and dependably create the little bunches of completely customized prescriptions required to convey cell treatments. At the other, it needs the high-volume, minimal effort


producing capacities important to convey modest insulin and immunizations against infections, for example, jungle fever that take such a large number of lives today in low-and center salary nations. Between these two extremes, organizations should quicken the advancement and commercialization of new particles to permit a more extensive scope of diseases to be tended to, and they should decrease fabricating costs, enhance quality, and assemble ability to widen access to the business' extraordinary items.

Just through a mix of solid science and profound operational greatness will the biopharma business have the capacity to satisfy its capability to change the wellbeing desires of a large number of individuals over the globe, effectively exploring both the promising and testing components of the part.

Global Pharmaceutical Market Growth Rate Percentage:



Projection of Pharma sales in Europe:



About Us

Our International Open Access Journals

- **700+ Leading**-edge Peer Reviewed Open Access Journals
- **21 Day** Rapid Review Process
- **50000+** Editorial Board Team, **35000+** Reviewers team
- **30 Million Readers** and High Visibility
- **1000+ Scientific Associations** Collaborations
- **100000+** facebook fans Likes
- **Publication** immediately after acceptance
- **Quality and Quick** editorial, review processing

Salient Features

- **Easy to Submit** and Review Systems
- **High Quality** and Fast Publishing Guaranteed
- **Unbiased, quality-oriented,** and transparent reviews
- **Truly impartial recognition** of the best papers
- **Feedback** on the impact of every article
- **Enhanced feature:** Audio version of published paper
- **Digital articles** to share and explore
- **Sharing option:** Social networking enabled
- Authors, reviewers and editors are provided with **scientific credits**
- User friendly/feasible website articles **translations** across more than **50 world languages**

Our International Scientific Conferences

- More than **3000 Conferences** happening across the globe
- Conferences organized in **Medical, Pharma, Engineering, Science, Technology and Business.**
- **CME/CPD Accredited** Conferences fostering professional and Personal development
- **Continuum of education** through organized scientific program
- **Renowned speakers** and scientists representing from **40 countries**
- **Highly Interactive sessions** and Panel Discussions
- **B2B Meetings** offers perfect platform for Global Networking

Salient Features

- **Robust on-line publicity** for all the speakers and organizing committee members
- **Career Guidance** Workshops for students and early career researchers
- **Accepted Abstracts** will be published in various **indexed journals**
- **Accepted abstracts** will be labeled with a **Digital Object Identification Number** (DOI) provided by **Cross Ref**
- **Creation** of speakers and abstracts pages in Google
- **Opportunity** to publish full Manu Scripts in our Open Access Journals

Special Issues : All accepted abstracts will be published inrespective Conference Series LLC Journals

Each abstract will be provided with digital Object Identifier by Crossref

About Conference

Euro Biopharma 2017 Conference website is attracting **25000+** Cell Therapy, Biopharmaceutics, Drug delivery, Biotechnology, Gene Therapy, Therapeutic Biological Products, BABE, Biosimilars, Clinical Trails, Drug Discovery, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, new scientific approaches to international regulatory standards. Biopharmaceutical Companies & Pharma market Analysis, who are working in this field. This unique opportunity that we extend to our speakers and attendees is not being offered by any other conference organizers. Through this the abstracts and research profiles of our speakers and organizing committee members getting global visibility which is an additional feature that you would be receiving in addition to networking opportunities before, during and after the conference.

How Conference Series Conferences differs from others?

- 3000+ Conferences across the globe in 30+ countries all through the year
- Over 25 Million+ Visitors and 20000+ Unique Visitors per conference
- Participation by Stalwarts from various international societies
- Internationally renowned speakers and scientists representation
- Career guidance for early career researchers and students
- Interesting scientific deliberations and discussions
- Perfect platform for Global Networking

Euro Biopharma 2017 salient features

- Meet Academia and Industry visionaries to get inspired
- Expand your knowledge and find solutions to problems
- Knowledge, Benchmarking and Networking offered at one place
- Forge connections and for global networking
- Highly Organized and Structured Scientific programs
- Poster presentations and world class exhibitions
- Meet with new vendors and suppliers



About Conference

Purpose

4th European Biopharma Congress is an arena for interdisciplinary exchange among professionals in the fields of Cell Therapy, Biopharmaceutics, Drug delivery, Biotechnology, Gene Therapy, Therapeutic Biological Products, BABE, Biosimilars, Clinical Trails, Drug Discovery, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, new scientific approaches to international regulatory standards. Biopharmaceutical Companies & Pharma market Analysis,.

Goals

- The conference program emphasizes evidence-based practice, educational innovation, practical application, and peer to peer networking and collaboration. The goals of the conference is to provide a transformative professional development experience through
- Bringing together the world's scientific experts to catalyze and advance scientific knowledge about Biopharmaceutics Congress present the most recent research findings, and promote and enhance scientific collaborations around the world.
- Bringing together community leaders, scientists, and policy leaders to promote and enhance programmatic collaborations to more effectively address regional, national and local responses to Elderly Population around the world and overcome barriers that limit access to care and services.

Objectives

After participating in this meeting, attendees should be able to

- Discuss emerging issues in Biopharmaceutics
- Discuss and apply recent research findings related to Biopharmaceutics & biotechnology
- Reflect on the place of critical distance in Biopharmaceutics & biotechnology

About Conference

Who should attend

4th European Biopharma Congress is exclusively designed for to the audience which includes interactive panel discussions, keynote lectures, plenary talks and poster sessions on the topics Cell Therapy, Biopharmaceutics, Drug delivery, Biotechnology, Gene Therapy, Therapeutic Biological Products, BABE, Biosimilars, Clinical Trails, Drug Discovery, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, new scientific approaches to international regulatory standards. Biopharmaceutical Companies & Pharma market Analysis, The conference invites delegates from Biopharma laboratories, Pharmacists, Academicians, Clinicians, Researchers, Health care professionals, students, business delegates and Young researchers across the globe providing a better podium, interconnecting the latest research, technological developments in the arena as well as therapeutic aspects.

About hosting organization

Conference Series is the world's leading specialist in organizing Academic, Scientific and Business conferences, meetings, symposiums and exhibitions in different verticals and horizontals like Medical, Pharma, Engineering, Science, Technology and Business to promote scientific research. Every year we host more than **3000+ global events** inclusive of **1000+ Conferences 1000+ Symposiums 1000+ Workshops** in **USA, Europe, Middle East and Asia** with the generous support and cooperation from our **30000+ Editorial Board Members, 1000+ Scientific Societies.** All the conference proceedings are published in the special issues of our **700+ Open Access International Journals** with the **DOI** provided by Crossref

Major sessions


- Biopharmaceutics: Drug Discovery and Development
- Therapeutic Biological Products
- Cellular and Gene Therapy
- Biologics and Biosimilars
- Bioavailability/Bioequivalence on Biopharmaceutical Products
- Clinical Trials on Biopharmaceutical Products
- Biotechnological Products
- Drug Delivery System
- Drug Disposition & Pharmacokinetics
- Biopharmaceutical Companies & Pharma market Analysis
- Pharmaceutical Regulatory Affairs And IPR
- Biopharmaceutical Pharmacovigilance
- Entrepreneurs Investment Meet
- Drug Dissolution
- Pharmacodynamics
- Oral Drug Absorption


About Conference

Supporting Journals

- Clinical Pharmacology & Biopharmaceutics:open access
- Bioeuivalance & Bioavaliability
- Drug Metabolism & Toxicology







Media partners/Sponsors

allied academies

AJF ANDREW JOHN PUBLISHING INC.

NEW YORK PRIVATE EQUITY FORUMS

About Conference

Exhibitors

We are Happy to announce to The ESCO GB Pharma As an Exhibitor For the conferences Euro Biopharma 2017. We Are To Associate with the ESCO GB Pharma.

ESCO GB Pharma Provides specialist services, equipment packages and process solutions leading to improved protection of operators, reduction of cross-contamination and more efficient processing, thereby advancing occupational health and human healthcare. Esco's VisionIs to provide enabling technologies for scientific discoveries to make human lives healthier and safer

Media Partner

European Pharmaceutical Review is the leading bimonthly publication for information on technologies in drug discovery and manufacturing. Every issue offers a high level of technical and business contributions from the worlds leading pharmaceutical companies and academic institutions, coupled with new and exciting features including interviews, updates and profiles.

Hospitals-Management is essentially a B2B online business and media platform that has under it wraps the largest global database of Healthcare buyers and suppliers. Hospitals-Management.com covers in-depth trends that shape industry dynamics and metamorphose global economics.

Manuscriptedit.com, your online partner for English language editing, proofreading, medical writing, formatting, design & development and publication support services.

About Vienna

Vienna is the capital and largest city of Austria. Vienna is the host to many major international organizations, the city is in eastern part of Austria near to Czech Republic, Slovakia and Hungary. City center was UNESCO World Heritage Site. Vienna is not only called City of Music but also called City of Dream is also well know for its Historical architecture Vienna is most prosperous city in the world. it best destination for international congresses and conventions Vienna is one of the wealthiest regions in the European Union: Its gross regional product of EUR 47,200 per capita constituted 25.7% of Austria's GDPAl together, approximately 8,300 new companies are being founded in Vienna every year since 2004. The majority of these companies are operating in fields of industry-oriented services, wholesale trade as well as information and communications technologies and new media. Vienna makes effort to establish itself as a start-up hub. The city of Vienna attaches major importance to science and research and focuses on creating a positive environment for research and development. During the late eighteenth century Vienna attracted composers from across Europe. Composers like Mozart, Haydn and Beethoven were drawn to the city by patronage of Habsburgs who were willing to support the music. Furthermore during the eighteenth century, except of the music development, a cultural development in the field of architecture and arts occured. The words elegance, grace, ymmetry and restrain are the most suitable words for the tendencies of the music, of art and the architecture of that period. Also in classical period a development in theatre and opera style was noticed..

Venue & Accommodation

Venue & Accommodation

Fleming's Hotel Wien-Westbahnhof

Neubaugürtel 26-28 | A-1070 Vienna,Austria



Contact Us

Sincerely Anil A

Program Director | Euro Biopharma 2017

Direct: (702) 508-5200 Ext: 8018

Customer Service: +1 (800) 216 6499

W: http://biopharmaceutics.pharmaceuticalconferences.com/europe/

E: eurobiopharma@pharmaceuticalconferences.org

Ph: +1-800-216-6499



Venue Map

Registrations

Academic

Only Registration: **USD 699**

Package A (Registration + 3 nights' Accommodation): **USD 1199**

Business

Only Registration: **USD 799**

Package A (Registration + 3 nights' Accommodation): **USD 1299**

Student

Student Oral: **USD 599**

Student Poster: **USD 499** (USD 399 + USD 100 for Poster)

Student Delegate: **USD 399**

E-poster: **USD 99**

Important Dates

Abstract Submission Opens: November 17, 2016

Registration Opens: November 17, 2016

Early bird Registration: June 15, 2017

On spot Registration: November 09, 2017

To register online, please visit:
http://biopharmaceutics.pharmaceuticalconferences.com/europe/